Dynavax Technologies | Ventas



Sales Cambio Fecha
AbbVie USD 15.1B 642M 2024-12
Adma Biologics USD 117.55M 2.29M 2024-12
Amgen USD 9.09B 583M 2024-12
AstraZeneca USD 14.89B 1.32B 2024-12
Biogen USD 2.45B 11.1M 2024-12
BioMarin Pharmaceutical USD 747.31M 1.57M 2024-12
Bristol-Myers Squibb USD 12.34B 450M 2024-12
Dynavax Technologies USD 72.03M 8.6M 2024-12
Gilead Sciences USD 7.57B 24M 2024-12
Glaxosmithkline GBP 8.12B 105M 2024-12
Merck USD 15.62B 1.03B 2024-12
Neurocrine Biosciences USD 627.7M 5.6M 2024-12
Novartis USD 13.15B 330M 2024-12
Pfizer USD 17.76B 61M 2024-12
Regeneron Pharmaceuticals USD 3.79B 70M 2024-12
Roche Holding CHF 31.64B 883M 2024-12
Sarepta Therapeutics USD 658.41M 191.24M 2024-12
TG Therapeutics USD 108.18M 24.31M 2024-12
Vertex Pharmaceuticals USD 2.91B 140.1M 2024-12



Dynavax Technologies Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.